296 related articles for article (PubMed ID: 25952404)
1. Correlating Parkinson's disease motor symptoms with three-dimensional [(18)F]FP-CIT PET.
Chung M; Park YS; Kim JS; Kim YJ; Ma HI; Jang SJ; Huh R; Kim HS; Kim WC
Jpn J Radiol; 2015 Oct; 33(10):609-18. PubMed ID: 25952404
[TBL] [Abstract][Full Text] [Related]
2. 18F-FP-CIT Positron Emission Tomography for Correlating Motor and Cognitive Symptoms of Parkinson's Disease.
Yang Y; Cheon M; Kwak YT
Dement Neurocogn Disord; 2017 Sep; 16(3):57-63. PubMed ID: 30906372
[TBL] [Abstract][Full Text] [Related]
3. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
Song IU; Chung YA; Oh JK; Chung SW
Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
[TBL] [Abstract][Full Text] [Related]
4. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
[TBL] [Abstract][Full Text] [Related]
5. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
[TBL] [Abstract][Full Text] [Related]
6. Right putamen and age are the most discriminant features to diagnose Parkinson's disease by using
Cascianelli S; Tranfaglia C; Fravolini ML; Bianconi F; Minestrini M; Nuvoli S; Tambasco N; Dottorini ME; Palumbo B
Hell J Nucl Med; 2017; 20 Suppl():165. PubMed ID: 29324935
[TBL] [Abstract][Full Text] [Related]
7. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages.
Wang J; Zuo CT; Jiang YP; Guan YH; Chen ZP; Xiang JD; Yang LQ; Ding ZT; Wu JJ; Su HL
J Neurol; 2007 Feb; 254(2):185-90. PubMed ID: 17334953
[TBL] [Abstract][Full Text] [Related]
8. The phase value of putamen measured by susceptibility weighted images in Parkinson's disease and in other forms of Parkinsonism: a correlation study with F18 FP-CIT PET.
Kwon GH; Jang J; Choi HS; Hwang EJ; Jung SL; Ahn KJ; Kim BS; Yoo IeR; Kim SH; Haacke EM
Acta Radiol; 2016 Jul; 57(7):852-60. PubMed ID: 26377263
[TBL] [Abstract][Full Text] [Related]
9. 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
Koros C; Simitsi A; Prentakis A; Beratis I; Papadimitriou D; Kontaxopoulou D; Fragkiadaki S; Papagiannakis N; Seibyl J; Marek K; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
Mov Disord; 2018 Nov; 33(11):1734-1739. PubMed ID: 30288781
[TBL] [Abstract][Full Text] [Related]
10. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease.
Eshuis SA; Maguire RP; Leenders KL; Jonkman S; Jager PL
Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):200-9. PubMed ID: 16228235
[TBL] [Abstract][Full Text] [Related]
11. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
[TBL] [Abstract][Full Text] [Related]
12. Extrastriatal
Nicastro N; Garibotto V; Burkhard PR
BMC Neurol; 2020 May; 20(1):192. PubMed ID: 32416724
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's disease.
Jang W; Park J; Shin KJ; Kim JS; Kim JS; Youn J; Cho JW; Oh E; Ahn JY; Oh KW; Kim HT
J Neurol Sci; 2014 Feb; 337(1-2):47-54. PubMed ID: 24289887
[TBL] [Abstract][Full Text] [Related]
14. Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson's disease patients.
Berti V; Pupi A; Ramat S; Vanzi E; De Cristofaro MT; Pellicanò G; Mungai F; Marini P; Sorbi S
Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2220-6. PubMed ID: 18649079
[TBL] [Abstract][Full Text] [Related]
15. Uneven age effects of [(18)F]FP-CIT binding in the striatum of Parkinson's disease.
Lee CS; Kim SJ; Oh SJ; Kim HO; Yun SC; Doudet D; Kim JS
Ann Nucl Med; 2014 Nov; 28(9):874-9. PubMed ID: 25008292
[TBL] [Abstract][Full Text] [Related]
16. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease.
Lorberboym M; Treves TA; Melamed E; Lampl Y; Hellmann M; Djaldetti R
Mov Disord; 2006 Apr; 21(4):510-4. PubMed ID: 16250023
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.
Benamer HT; Patterson J; Wyper DJ; Hadley DM; Macphee GJ; Grosset DG
Mov Disord; 2000 Jul; 15(4):692-8. PubMed ID: 10928580
[TBL] [Abstract][Full Text] [Related]
18. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
[TBL] [Abstract][Full Text] [Related]
19. Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of FP-CIT single photon emission computed tomography.
Eggers C; Kahraman D; Fink GR; Schmidt M; Timmermann L
Mov Disord; 2011 Feb; 26(3):416-23. PubMed ID: 21264942
[TBL] [Abstract][Full Text] [Related]
20. Relationship between [
Ramani L; Malek N; Patterson J; Nissen T; Newman EJ
Acta Neurol Scand; 2017 Apr; 135(4):400-406. PubMed ID: 27255673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
